U.S. markets open in 5 hours 15 minutes

  • S&P Futures

    4,664.75
    -15.00 (-0.32%)
     

  • Dow Futures

    35,459.00
    -112.00 (-0.31%)
     

  • Nasdaq Futures

    16,304.00
    -78.00 (-0.48%)
     

  • Russell 2000 Futures

    2,314.60
    -17.60 (-0.75%)
     

  • Crude Oil

    75.65
    -1.10 (-1.43%)
     

  • Gold

    1,801.60
    -4.70 (-0.26%)
     

  • Silver

    24.00
    -0.30 (-1.24%)
     

  • EUR/USD

    1.1278
    +0.0036 (+0.32%)
     

  • 10-Yr Bond

    1.6250
    0.0000 (0.00%)
     

  • Vix

    20.17
    +2.26 (+12.62%)
     

  • GBP/USD

    1.3391
    -0.0006 (-0.04%)
     

  • USD/JPY

    114.6780
    -0.1620 (-0.14%)
     

  • BTC-USD

    56,297.56
    -1,503.96 (-2.60%)
     

  • CMC Crypto 200

    1,403.23
    -7.82 (-0.55%)
     

  • FTSE 100

    7,219.47
    -35.99 (-0.50%)
     

  • Nikkei 225

    29,774.11
    +28.24 (+0.09%)
     

Infectious Disease Market Size to Grow by USD 62.83 bn | Increasing Prevalence of Infectious Diseases to Boost Growth | Technavio

·5 min read

NEW YORK, Nov. 23, 2021 /PRNewswire/ -- The infectious disease market size is expected to grow by USD 62.83 bn from 2020 to 2025, decelerating at a CAGR of 10.19%, according to Technavio. The report offers an up-to-date analysis as well as exact growth variance and the Y-O-Y growth rate

Attractive Opportunities in Infectious Disease Market by Product and Geography - Forecast and Analysis 2021-2025
Attractive Opportunities in Infectious Disease Market by Product and Geography - Forecast and Analysis 2021-2025

Request a Free Sample Report to explore growth opportunities in the infectious disease market

The infectious disease market is fragmented, and the degree of fragmentation will decelerate during the forecast period. To make the most of the opportunities, market vendors should focus more on the growth prospects in the fast-growing segments while maintaining their positions in the slow-growing segments.

The infectious disease market report covers the following areas:

Infectious Disease Market 2021-2025: Segmentation

  • Product

  • Geography

To learn more about the contribution of various market segments, Download a Free Sample

Infectious Disease Market 2021-2025: Scope

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources.

The increasing prevalence of infectious diseases, growing awareness of infectious diseases, and strong drug pipeline will offer immense growth opportunities. However, generic erosion, adverse effects of anti-infective drugs, and slowdown in the manufacturing industry will challenge the growth of the market participants.

Infectious Disease Market 2021-2025 : Vendor Analysis

We provide a detailed analysis of around 25 vendors operating in the infectious disease market, including AbbVie Inc., Boehringer Ingelheim International GmbH, F. Hoffmann-La Roche Ltd., Gilead Sciences Inc., GlaxoSmithKline Plc, Johnson and Johnson Inc., Merck and Co. Inc., Pfizer Inc., Sanofi SA, and Takeda Pharmaceutical Co. Ltd. Backed with competitive intelligence and benchmarking, our research report on the infectious disease market is designed to provide entry support, customer profile, and M&As as well as go-to-market strategy support.

Subscribe to our "Lite Plan" billed annually at USD 3000 that enables you to download 3 reports/year and view 3 reports/month.

Infectious Disease Market 2021-2025: Regional Analysis

Technavio offers an up-to-date analysis of the geographical composition of the market as well as competitive intelligence and regional opportunities for vendors. According to our research, 40% of the market's growth is expected to originate from North America during the forecast period. The US is the key country for the infectious diseases market in North America. The region has been recording a significant growth rate. Hence, it is expected to offer several growth opportunities to market vendors during the forecast period. The growing awareness of infectious diseases will facilitate the infectious disease market growth in North America during the forecast period.

Infectious Disease Market 2021-2025: Key Highlights

  • CAGR of the market during the forecast period 2021-2025

  • Detailed information on factors that will assist infectious disease market growth during the next five years

  • Estimation of the infectious disease market size and its contribution to the parent market

  • Predictions on upcoming trends and changes in consumer behavior

  • The growth of the infectious disease market

  • Analysis of the market's competitive landscape and detailed information on vendors

  • Comprehensive details of factors that will challenge the growth of infectious disease market vendors

Related Reports:

  • Covid-19 Vaccination Market: The Covid-19 vaccination market has been segmented by application (mRNA and others) and geography (North America, Asia, Europe, and ROW). Download Free Sample Report

  • Glioblastoma Multiforme Treatment Market: The glioblastoma multiforme treatment market has been segmented by end-user (hospitals, clinics, and ambulatory surgical centers) and geography (North America, Europe, Asia, and ROW). Download Free Sample Report

Infectious Disease Market Scope

Report Coverage

Details

Page number

120

Base year

2020

Forecast period

2021-2025

Growth momentum & CAGR

Decelerate at a CAGR of 10.19%

Market growth 2021-2025

USD 62.83 billion

Market structure

Fragmented

YoY growth (%)

16.04

Regional analysis

North America, Europe, Asia, and ROW

Performing market contribution

North America at 40%

Key consumer countries

US, Germany, UK, China, and Japan

Competitive landscape

Leading companies, competitive strategies, consumer engagement scope

Companies profiled

AbbVie Inc., Boehringer Ingelheim International GmbH, F. Hoffmann-La Roche Ltd., Gilead Sciences Inc., GlaxoSmithKline Plc, Johnson and Johnson Inc., Merck and Co. Inc., Pfizer Inc., Sanofi SA, and Takeda Pharmaceutical Co. Ltd.

Market Dynamics

Parent market analysis, market growth inducers and obstacles, fast-growing and slow-growing segment analysis, COVID-19 impact and future consumer dynamics, market condition analysis for the forecast period

Customization purview

If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

About Us

Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contact

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/

Technavio (PRNewsfoto/Technavio)
Technavio (PRNewsfoto/Technavio)
Cision
Cision

View original content to download multimedia:https://www.prnewswire.com/news-releases/infectious-disease-market-size-to-grow-by-usd-62-83-bn--increasing-prevalence-of-infectious-diseases-to-boost-growth--technavio-301429926.html

SOURCE Technavio

Recommended Stories

  • Why Nio Stock Blasted Higher Today

    Investors in Nio (NYSE: NIO) are finally getting a breather, as the electric vehicle (EV) stock began the week on a solid note after plunging nearly 9% last week. As of 12:30 p.m. ET Monday, Nio was trading up 7.3% after having surged 10.8% earlier in the day on rumors about its much-awaited flagship luxury sedan,the ET7, touted to compete with Tesla (NASDAQ: TSLA). Earlier this month, Nio dropped a bomb when it reported a sharp decline in deliveries for October, down 27.5% year over year, even as rivals continued to race ahead.

  • U.S. wants more oil, but OPEC+ can't turn on the tap much harder

    U.S. pressure on OPEC+ to pump more oil and cool red-hot crude prices has shone a spotlight on a relatively new problem for the producer group: it doesn't have much extra capacity to hike output faster, even if it wanted to. Yet OPEC+ can't even hit those goals. Production by OPEC+ was 700,000 bpd less than planned in both September and October, according to the International Energy Agency (IEA), raising the prospect of a tight market and high oil prices for longer.

  • Princes to paupers: India's salesmen face ruin as tycoon Ambani targets mom-and-pop stores

    For eight straight days, household goods salesman Vipresh Shah has failed to sell a single pack of Dettol soap to the storekeepers who have been buying from him ever since he took over his family business as a teenager, 14 years ago. Shah is an official distributor for Britain's Reckitt Benckiser in Vita, near Sangli city, around 200 miles south of Mumbai. "As Reckitt's distributor, I used to be like a prince in the market," said Shah.

  • Top Tech Stocks for December 2021

    The technology sector is composed of businesses that sell goods and services in electronics, software, computers, artificial intelligence (AI), and other industries related to information technology (IT). The sector includes companies with the largest market capitalizations in the world, such as Apple Inc. (AAPL), Microsoft Corp. (MSFT), and Amazon.com Inc. (AMZN). Tech stocks, represented by the Technology Select Sector SPDR Fund (XLK), have outperformed the broader market over the past year.

  • Social Security Isn’t Going Broke. But Prepare for Potential Benefits Cuts.

    Given some worrisome recent news about the program, clients are asking more questions. Here’s what advisors are saying.

  • Is Pfizer Stock A Buy After Winning Broad Covid Booster Authorization?

    Is Pfizer stock a buy after U.S. officials allowed Covid boosters for all adult who received messenger RNA shots? Is PFE stock a buy now?

  • 4 Energy Stocks Pumping Out Tons of Cash

    Energy investors are looking for growing dividends, and one of the best ways to spot companies that could increase their payouts is to look for those pumping out the most free cash flow. One measure of the strength of a company’s free cash flow—and its possible investibility — is its free cash flow yield. The yield divides the company’s free cash flow by its market cap, giving a better sense of how investors are valuing the company’s cash production.

  • Oil slips on plans to tap emergency crude reserves

    Oil prices fell on Tuesday, reversing gains the previous session on talk the United States, Japan and India will release crude reserves to tame prices despite the threat of faltering demand as COVID-19 cases flare up in Europe. The United States is expected to announce a loan of crude oil from its emergency stockpile on Tuesday as part of a plan it hashed out with major Asian energy consumers to lower energy prices, a Biden administration source familiar with the situation said. Brent crude futures fell 67 cents, or 0.8%, to $79.03 a barrel at 0721 GMT, while U.S. West Texas Intermediate (WTI) crude futures fell 88 cents, or 1.2%, to $75.87 a barrel.

  • ‘Indentured servitude’: low pay and grueling conditions fueling US truck driver shortage

    Long hours and poor working conditions have aggravated a ‘driver retention problem’ worsening the supply chain crisis Truckers take a break at the Love’s travel stop in Springville, Utah. Photograph: George Frey/Getty Images At Joe’s Travel Plaza, a neon-lit rest stop on California’s main interstate highway, truckers can get a brief respite from life on the road. There’s a TV lounge, a laundry room and a free shower if you buy at least 75 gallons of fuel. There’s even a pair of massage chairs in

  • U.S. imposes further sanctions in connection with Nord Stream 2 gas pipeline

    The State Department submitted a report to the U.S. Congress listing two vessels and an entity, Transadria Ltd., involved in the pipeline, Blinken said, but did not give details on the second vessel. Washington opposes the $11 billion pipeline, which runs under the Baltic Sea to bypass Ukraine and carry gas from Russia's Arctic region to Germany.

  • Apple told workers they can discuss wages and working conditions as one more #AppleToo leader left the company

    Following charges that it is preventing employees from discussing their pay and working conditions, Apple issued an memo stating that they have that right. But it comes as Cher Scarlett, one of the leaders of the movement to hold the company to account, has left the tech giant.

  • Endo's Qwo® (collagenase clostridium histolyticum-aaes) Data Presented at the American Society for Dermatologic Surgery's Annual Meeting

    Endo International plc (NASDAQ:ENDP) announced today that data from clinical and non-clinical studies of Endo Aesthetics' Qwo® (collagenase clostridium histolyticum-aaes), which received FDA approval in July 2020 for the treatment of moderate to severe cellulite in the buttocks of adult women, were presented during the annual meeting of the American Society for Dermatologic Surgery (ASDS).

  • Samsung to Name U.S. Plant Location This Week, Yonhap Says

    (Bloomberg) -- Samsung Electronics Co. will announce the location of its new chip plant in the U.S. this week, following Vice Chairman Jay Y. Lee’s trip to the country and Canada, Yonhap News reported.Most Read from BloombergNew York City Is Building a Wall of Oysters to Fend Off FloodsA Denser City, But at What Cost?The Women Behind Historic House DesignsFrom Bathhouses to Fisheries, Hidden Inflation Is Creeping Across JapanMaverick 70-Year-Old CEO Is Determined to Shake Up Japanese FinanceTayl

  • Pfizer-BioNTech's COVID-19 Vaccine Shows 100% Effectiveness In Long Term Analysis In Adolescents

    Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) have announced topline results from a longer-term analysis of the safety and efficacy of their COVID-19 Vaccine in individuals 12 through 15 years of age. The updated findings from the Phase 3 trial show that a two-dose series of the Vaccine (30-µg per dose) was 100% effective against COVID-19, measured seven days through over four months after the second dose. Data from almost 2,230 participants showed that 30 cases of COVID-19 were reported

  • Natural Gas Stocks Are Down. Now’s the Chance to Buy This New Contender.

    Coterra Energy is more committed than most of its rivals to returning cash to shareholders, and is well-positioned financially to benefit from strong natural gas demand.

  • How Alnylam Pharmaceuticals Could Take On Pfizer With A 'Catalyst-Rich' 2022

    Alnylam stock popped to a month high Monday after the company at its research and development day unveiled "a catalyst-rich calendar" for 2022.

  • Want to Bet on Bitcoin Without Owning Any? Try These Mining Stocks.

    Miners like Riot Blockchain and Marathon Digital offer potential profit growth and are a cheaper way to play the digital currency.

  • Activision Blizzard CEO might step down amid sexual harassment scandal

    Activision Blizzard CEO Bobby Kotick said that he may step down as his company faces a sexual harassment scandal. Yahoo Finance's Daniel Howley details the latest.

  • Natural Gas Price Forecast – Natural Gas Markets Hanging on By a Thread

    Natural gas markets have fallen again during the day on Monday but have also turned around to show signs of life at the previous uptrend line. In that sense, we are hanging on by a thread.

  • Supply-Chain Problems Show Signs of Easing

    Bottlenecks are clearing in some places, executives and economists say, but the prospect of more Covid-19 outbreaks raises concerns that some supply-chain snarls could persist into next year.